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Type III secretion systems (T3SS) are conserved in many pathogenic gram-negative bacteria. Small mole-
cules that specifically target T3SS in Yersinia and Chlamydia spp. have recently been identified. Here we show
that two such compounds inhibit Salmonella T3SS-1, preventing secretion of T3SS-1 effectors, invasion of
cultured epithelial cells, and enteritis in vivo.
Salmonellae are important human and animal bacterial
pathogens which cause a spectrum of diseases ranging from
gastroenteritis to typhoid fever. Nontyphoidal salmonellosis
involves acute intestinal inflammatory and secretory responses
which are induced upon the interaction of intestinal epithelial
cells with the pathogen (18). A type III secretion system
(T3SS-1), encoded within the inv-spa-prg (SPI-1) chromosomal
locus, is essential for the ability of Salmonella enterica serovar
Typhimurium to invade enterocytes and induce enteritis (19).
Structural components of T3SS-1 form the secretion organelle
known as the needle complex. This multiprotein structure
spans both inner and outer bacterial membranes and functions
to secrete Salmonella virulence-associated proteins. The se-
creted proteins SipB, SipC, and SipD permit translocation of
other secreted proteins, known as effectors, by forming a pore
in the eukaryotic cell membrane through which effector pro-
teins pass. The effector proteins are delivered into host cells
and act in concert to elicit a variety of cellular responses for the
benefit of the pathogen (for a review see reference 3). Muta-
tional inactivation of genes encoding the structural or regula-
tory components of T3SS-1, or in the three sip genes, com-
pletely abolishes effector protein translocation, Salmonella
invasion (7, 8), and enteropathogenesis (22). Inactivation of
genes encoding individual effector proteins results in a partial
attenuation (6) in a bovine ligated ileal loop model of in-
fection.
T3SSs are conserved in a variety of gram-negative animal
and plant pathogenic and symbiotic bacteria and deliver a set
of effectors (unique for each bacterial pathogen) into host
cells, which then subvert, inhibit, or activate cellular pathways.
The conservation of structural components of T3SSs and their
importance for virulence in many bacterial pathogens make
them an attractive target for chemical inhibition (2, 15). Re-
cently, a class of small-molecule inhibitors specifically targeting
the T3SS of Yersinia spp. has been identified. It has been shown
that these compounds inhibit T3SS-dependent protein trans-
location and, thus, Yersinia virulence (9, 13). Moreover, the
same or similar compounds have also been shown to inhibit
type III secretion (T3S) in enteropathogenic Escherichia coli
(4) and Chlamydia trachomatis (12, 23). Here we report that
two of these compounds, which are inhibitors of the Yersinia
T3SS (13), are also effective inhibitors of Salmonella T3SS-1.
Small-molecule inhibitors of Yersinia T3SS affected protein
secretion via Salmonella T3SS-1 but had no effect on bacterial
growth. Several compounds identified as small-molecule inhib-
itors of the Yersinia pseudotuberculosis T3SS (13) were tested
for their ability to inhibit the T3SS-1 of Salmonella. The com-
pounds used in this study were provided by Innate Pharma-
ceuticals and were prepared according to published procedures
(1). All compounds were 95% pure according to 1H nuclear
magnetic resonance spectroscopy. Initially the ability of these
compounds to impair T3SS-1-mediated secretion in vitro was
assessed. This assay relies on the fact that when Salmonella
cultures are grown under T3SS-1-inducing conditions (a tem-
perature shift from 25°C to 37°C), they secrete a distinct set of
proteins (T3SS-1 effectors known as Sips and Sops) via T3SS-1
into the culture supernatant. These proteins are the major
constituents of the culture supernatant when cultures are
grown in this way. A nalidixic acid-resistant mutant of S. en-
terica serovar Typhimurium, Salmonella serovar Typhimurium
strain 4/74 (11), was used throughout these studies. Bacteria
were cultured overnight in 10 ml Luria Bertani (LB) broth at
25°C with agitation. Cultures were diluted 10-fold into LB
broth. Test compounds were added to a final concentration of
100 M, a concentration which effectively inhibits Yersinia T3S
(13). Control cultures were incubated with a dimethyl sulfoxide
(DMSO) vehicle at the same concentration as that present in
the test samples (0.1% vol/vol). Cultures were incubated at
37°C with agitation for 4 h. Samples were taken for bacterial
enumeration at intervals during the incubation period. At 4 h
of incubation, bacteria were pelleted by centrifugation, and the
supernatant was passed through a 0.45-m-pore-size low pro-
tein-binding filter. Secreted proteins were precipitated by the
addition of trichloroacetic acid (final concentration, 10% vol/
vol) and collected by centrifugation at 10,000  g for 30 min at
4°C. Protein pellets were washed with acetone and resus-
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pended in sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) loading buffer. Proteins were purified
from cultures containing similar numbers of bacteria, and iden-
tical volumes of reagents were used during processing; thus,
any differences in the amounts of protein were not due to
differences in the numbers of bacteria. Identical volumes of
protein samples were analyzed by SDS-PAGE and Coomassie
blue staining, and the amounts of proteins from samples cul-
tured in the presence of inhibitors were compared to amounts
from the DMSO control sample by eye. Significant inhibition
was arbitrarily determined by whether the compounds resulted
in overall lower amounts of protein on the Coomassie gel than
that of the control. Several compounds were found to impair
T3SS-1-dependent protein secretion (data not shown). Based
on this initial assessment, INP0007 and INP0403, previously
described as compound 1 and compound 11, respectively, in
the literature (13) and sharing a common structural motif
present in acylated hydrazones of salicylic aldehydes (Fig. 1a),
were identified as having the greatest effect on the level of
secreted proteins (Fig. 1b) and were chosen for further anal-
ysis. The inhibition of T3SS-1-mediated protein secretion was
not a result of inhibition of bacterial viability and growth, as
viable bacterial counts were the same in the presence or ab-
sence of the compounds at all time points examined (Fig. 1c).
Both INP0007 and INP0403 acted in a dose-dependent man-
ner and were not cytotoxic. To determine the optimal concen-
tration of a compound required to inhibit Salmonella T3SS-1
for use in further studies, we repeated the secreted protein
experiment for INP0007 and INP0403, using a range of con-
centrations of the compounds from 10 to 100 M. Proteins
were collected from the filtered culture supernatants by incu-
bating with 30 l of StrataClean resin (Stratagene). The resin
was washed in phosphate-buffered saline (PBS) and resuspended
in SDS-PAGE loading buffer. Both compounds showed a dose-
dependent inhibition of T3SS-1-mediated protein secretion,
though INP0403 was more effective (Fig. 2a). INP0403 did
show substantial inhibition at the lowest concentration of 10
M, but as 100 M had a greater effect, we utilized this
concentration for both compounds for the remainder of the
studies.
Since further experiments would require the use of the com-
pounds in cell-based assays, we sought to determine whether
INP0007 and INP0403 were cytotoxic. HeLa cells cultured in
Dulbecco’s modified Eagle’s medium containing 10% fetal bo-
FIG. 1. The structure of INP0007 and INP0403 (a) and their effect
on secretion of T3SS-1 effector proteins and bacterial viability. Bacte-
ria were cultured under T3SS-1-inducing conditions in LB medium
supplemented with DMSO, INP0007, or INP0403. (b) INP0007 and
INP0403 inhibit protein secretion via T3SS-1. Secreted proteins were
isolated from culture supernatants at 4 h, separated by SDS-PAGE,
and stained with Coomassie blue. Protein samples were confirmed to
have derived from cultures containing equivalent numbers of bacteria.
(c) Inhibition of T3SS-1-mediated protein secretion is not due to
inhibition of bacterial growth by INP0007 and INP0403. Viable bac-
teria were enumerated by taking triplicate aliquots from cultures at
hourly intervals and plating serial dilutions onto LB agar. Values are
the mean log10 CFU/ml of triplicate counts, and error bars indicate
standard deviations from the mean.
FIG. 2. INP0007 and INP0403 exhibit dose-dependent effects on
T3SS-1-mediated protein secretion and are not cytotoxic in vitro. (a)
INP0403 can inhibit Salmonella T3SS-1-mediated protein secretion at
a range of concentrations from 10 to 100 M. Bacteria were cultured
under T3SS-1-inducing conditions in LB medium supplemented with
DMSO or INP0403. Secreted proteins were isolated from culture su-
pernatants at 4 h and were subjected to SDS-PAGE followed by
Coomassie staining. (b) INP0007 and INP0403 were added to HeLa
cells at concentrations ranging from 0.1 to 100 M and incubated for
3 h. Cell viability was determined using CellTiter96 AQueous one-
solution cell proliferation assay (Promega) and is expressed as the
percentage of DMSO control. Values represent the means of three
independent experiments performed with triplicate samples. Error
bars indicate standard deviations from the mean.
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vine serum were seeded in 96-well plates and incubated over-
night at 37°C in 5% CO2. INP0007 and INP0403 were added to
the HeLa cells in a range of concentrations from 0.1 to100 M
and incubated at 37°C in 5% CO2 for 3 h. Cytotoxicity was
measured using a CellTiter96 AQueous one-solution cell pro-
liferation assay (Promega) according to the manufacturer’s
instructions. After 3 h, neither INP0007 nor INP0403 had a
toxic effect at concentrations of 0.1 to 10 M (Fig. 2b). Any
slight cytotoxic effect of INP0403 at the highest concentration
of 100 M was offset by the fact that the compounds were
added to bacterial cultures at 100 M but were then further
diluted in the in vitro assays. Thus, effects seen in in vitro
studies would be attributable to the specific activity of the
compounds on T3S and not any cytotoxic effect.
INP0007 and INP0403 inhibited T3SS-1-associated viru-
lence phenotypes in vitro. To further analyze the effect of
INP0007 and INP0403 on the function of T3SS-1, we assessed
whether these compounds could inhibit Sip-mediated pore-
forming activity against erythrocyte membranes. Previous stud-
ies using several bacterial species have demonstrated that their
respective T3SSs cause contact-dependent hemolysis of red
blood cells in vitro (5, 16, 21). This is probably due to leakage
of hemoglobin through the translocation pore formed in the
membrane of the erythrocyte (14). Recently, a modified form
of this hemolysis-based assay was used to evaluate expression
of T3SS-1 in Salmonella in a rapid, simple, and reliable manner
(10). Since DMSO was expected to affect the integrity of eryth-
rocyte membranes, we preincubated bacteria with inhibitors
prior to their use in the hemolysis assay. Salmonella serovar
Typhimurium 4/74 was cultured overnight in LB broth at 25°C
with agitation. Aliquots from the overnight culture were di-
luted 10-fold into prewarmed LB broth. INP0007, INP0403, or
DMSO alone was added into each respective subculture and
incubated at 37°C for 1 h. Bacteria were recovered by centrif-
ugation, washed in PBS, resuspended in fresh LB medium, and
assessed for their ability to lyse sheep red blood cells as de-
scribed previously (10), with the modification that a red blood
cell-PBS suspension was used. This assay gave an absorbance
reading which was normalized to a negative control containing
no bacteria to remove background lysis. The normalized read-
ings for the DMSO or inhibitor samples were then expressed as
“hemolytic activity as percentage of wild-type,” where the wild-
type was untreated bacteria and was taken as 100%. Bacteria
preincubated with either compound showed a reduction in
contact-dependent hemolysis compared to that mediated by
Salmonella serovar Typhimurium strain 4/74 preincubated with
DMSO (Fig. 3a).
As it is well established that effector proteins delivered by
T3SS-1 mediate the invasion of Salmonella into epithelial cells
by stimulating rearrangements of the subcortical actin cy-
toskeleton, we assessed whether INP0007 and INP0403 would
impair the invasion of HeLa cells by Salmonella serovar Ty-
phimurium strain 4/74. Bacteria were cultured overnight at
25°C with agitation, diluted 10-fold into fresh LB containing
INP0007, INP0403, or DMSO, and cultured for a further hour
at 37°C to induce T3SS-1 effector protein expression. Bacteria
were used to infect HeLa cells at a multiplicity of infection of
approximately 10. The invasion assay was performed essen-
tially as described previously (24). Briefly, following a 30-min
incubation of bacteria with the HeLa cells, cells were washed
with PBS, and gentamicin (150 g/ml) was added to the culture
medium for 30 min to kill extracellular bacteria, after which
the HeLa cells were washed three times with PBS and lysed
with 1% (vol/vol) Triton X-100 in PBS. Intracellular bacteria
were enumerated by plating serial dilutions onto LB agar. The
presence of either INP0007 or INP0403 resulted in a reduc-
tion, 47% for INP0007 and 60% for INP0403, in bacterial
invasion of HeLa cells compared to that for the DMSO control
(Fig. 3b). These reductions in invasion are comparable to those
seen with mutations in T3SS-1 genes required for invasion, for
example, the sopE gene (17, 23).
The fact that both contact-dependent hemolysis and eukary-
otic cell invasion are not completely prevented is most likely
due to the reversible effect of the compounds, as observed for
Yersinia (13), allowing the bacteria to regain some or most of
their T3S activity when the compounds are washed out, in the
case of the hemolysis assay, or diluted out upon addition of
bacteria to cell culture medium, in the invasion assay. Never-
theless, taken together, these data suggest that both INP0007
FIG. 3. Inhibition of T3SS-1-associated virulence phenotypes in
vitro by INP0007 and INP0403. (a) Preincubation of Salmonella cul-
tures with INP0007 or INP0403 suppresses T3SS-1-mediated contact-
dependent hemolysis. Bacteria were preincubated with 100 M com-
pounds for 1 h at 37°C, before being washed and incubated with sheep
red blood cells for 4 h. Hemolytic activity is presented as the percent-
age of the wild-type strain, which was taken as 100%. Values represent
the means of two independent experiments performed with triplicate
samples. Error bars indicate standard deviations from the means. (b)
Preincubation of Salmonella cultures with INP0007 or INP0403 inhib-
its bacterial invasion of eukaryotic cells in vitro. HeLa cell monolayers
were infected at a multiplicity of infection of 10 with Salmonella sero-
var Typhimurium strain 4/74 cultured for 1 h in the presence of 100
M compounds (final compound concentration of 4.5 M in the in-
vasion assay). Thirty minutes postinfection, extracellular bacteria were
killed with the addition of gentamicin, and 1 h postinfection, cells were
lysed, and viable intracellular bacteria were enumerated by plating
serial dilutions on LB agar. Values are the mean log10 CFU/ml of
triplicate counts, and error bars indicate standard deviations from the
means.
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and INP0403 are able to inhibit T3SS-1 secretion and T3SS-
1-associated virulence phenotypes in vitro.
Preincubation of S. enterica serovar Typhimurium with
INP0007 or INP0403 suppressed T3SS-1-induced secretory
and inflammatory responses in vivo. The effect of INP0007
and INP0403 on the induction of T3SS-1-mediated intestinal
secretory and inflammatory responses by S. enterica serovar
Typhimurium was assessed in a bovine intestinal ligated loop
model. Salmonella serovar Typhimurium 4/74 was grown over-
night at 25°C with agitation, diluted 10-fold into fresh LB
medium, and grown for 1.5 h at 37°C with agitation. Two
approaches were taken to assess the effect of the compounds:
either 100 M compound or 0.1% (vol/vol) DMSO was added
to the bacteria for the 1.5-h incubation period (preincubated),
or both were added to the bacteria immediately prior to injec-
tion into the bovine intestinal ligated loops (coinjected). The
experimental procedures were performed essentially as de-
scribed previously (20), in accordance with the Animals (Sci-
entific Procedures) Act of 1986 and with the approval of the
local ethical review committee. Three ca. 4-week-old Friesian
bull calves were confirmed to be culture negative for Salmo-
nella, placed under terminal anesthesia, and underwent a lap-
arotomy. Ligated loops (6 cm) were constructed in the mid
ileum, and each treatment was tested in triplicate, with 5 ml of
bacterial culture injected into discrete loops in a semirandom-
ized order. Neutrophils were isolated from jugular blood after
induction of anesthesia, radiolabeled with 111In-oxinate, and
reinjected within an hour of loop inoculation as described
previously (20). Twelve hours after loop inoculation, calves
were killed with an overdose of sodium pentobarbitone, the
loops were excised and the volume of fluid accumulated was
measured, and radioactivity associated with loop contents and
mucosa was quantified. Statistical analysis (t test) of the results,
comparing the effect of the various chemical treatments to
those of Salmonella cultured in the presence of DMSO alone,
was peformed using Minitab statistical software (release
14.13). P values of 0.05 were considered significant.
An internal control strain of Salmonella serovar Typhi-
murium 4/74 harboring a transposon insertion in prgH (prgH::
miniTn5Km2 [11]), a key structural component of T3SS-1,
confirmed that the model is capable of detecting T3SS-1-me-
diated enteritis in calves (P  0.02 for both secretory and
inflammatory responses; Fig. 4a and b). The magnitude of the
secretory and inflammatory responses elicited by Salmonella
FIG. 4. Salmonella serovar Typhimurium-induced intestinal secretory and inflammatory responses in calves can be inhibited by preincubation
of the bacteria with INP0007 and INP0403 but not by treatment of the bacteria with chemicals at the time of loop inoculation. (a) Secretory
responses to the Salmonella serovar Typhimurium 4/74 wild-type and the prgH mutant strains confirmed that the model is able to detect
T3SS-1-mediated enteritis. Values for Salmonella serovar Typhimurium 4/74 grown in the presence of INP0007 or INP0403 (preincubated) or
treated immediately prior to loop inoculation (coinjected) are also shown together with negative controls comprising sterile LB medium with or
without inhibitors or vehicle. The means of the ratio of volume (V, in ml)/loop length (L, in cm) from triplicate determinations in each calf were
calculated. Values shown on the graph represent the mean V/L from three separate calves  the standard error of the means (SEM). (b)Parallel
determinations of the recruitment of radiolabeled neutrophils into the inoculated loops. The total amount of radioactivity associated with the loop
contents and mucosa for each treatment was determined. The polymorphonuclear leukocyte (PMN) influx represents the n-fold induction of
inflammatory responses relative to that of the LB medium only control, and the values represent the means  SEM of three biological replicates.
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serovar Typhimurium 4/74 preincubated with INP0007 or
INP0403 for 1.5 h prior to injection into the loops was lower
than that elicited by Salmonella serovar Typhimurium 4/74
preincubated with DMSO control (Fig. 4a and b), indicating
that both chemicals suppressed enteric virulence of Salmonella
in vivo. The reduced secretory response elicited when Salmo-
nella serovar Typhimurium 4/74 was pretreated with INP0403
(Fig. 4a) was statistically significant (P  0.0001) compared to
that of Salmonella serovar Typhimurium 4/74 cultured with
DMSO alone. However, when INP0007 and INP0403 were
coinjected into loops alongside the Salmonella inoculate there
was no significant suppression of secretory and inflammatory
responses (P 0.7380 and P 0.9998 for INP0007; P 0.9690
and P  1.0 for INP0403; Fig. 4a and b). This could be ex-
plained by a rapid dilution of the chemicals by intestinal fluids
and/or by their absorption by intestinal epithelia or their inac-
tivation by intestinal enzymes. Elevated secretory or inflam-
matory responses were not observed for the loops injected with
the chemicals or with DMSO alone.
Concluding comments. Our work, together with previously
published studies of Yersinia, clearly demonstrates the poten-
tial of INP0007 and INP0403 to inhibit the activity of distantly
related T3SSs, making such compounds attractive as potential
antiinfective agents. By disarming a key virulence factor with-
out affecting bacterial replication, it is anticipated that resis-
tance to such compounds may be less likely to develop than
with conventional antimicrobials. While additional studies will
be required to determine the active concentration, stability,
and toxicity of such inhibitors at relevant sites in vivo, we assert
that further work is needed to develop the therapeutic poten-
tial of INP0007 and INP0403 and their derivatives.
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